Table 2.
Primers used to perform complete sequencing of drug target genes
| Primera | Nucleotide sequence (5′–3′) | Positionb | Product size (bp) | Source or reference |
|---|---|---|---|---|
| PCR primers | ||||
| rpoB-F1 | GCACCGCTCCTCTAAGGGCTCT | –54 to –33 | 3,624 | This study |
| rpoB-R1 | GAGCACGTAACTCCCTTTCCCCTA | 3569 to 3546 | ||
| katG-F1 | TCAGCGCACGTCGAACCTGTCGAG | 1 to 24 | 2,223 | This study |
| katG-R1 | GTGCCCGAGCAACACCCACCCATTA | 2223 to 2109 | ||
| gyrA-F1 | TTCCTGGATGTCTAACGCAAC | –48 to –28 | 2,616 | This study |
| gyrA-R1 | ATTCCTCCTCAGATCGCTACG | 2567 to 2547 | ||
| gyrB-F1 | GACGCACCAGGAAGAAAGATGT | –41 to –20 | 2,237 | This study |
| gyrB-R1 | ACGTCGTGTCTGTCATCTAT | 2195 to 2176 | ||
| rrs-F1 | TACCTTTGGCTCCCTTTTCC | –35 to –16 | 1,617 | This study |
| rrs-R1 | ACGGCCTACGCCCCACCAGT | 1581 to 1562 | ||
| Sequencing primersc | ||||
| rpoB-F2 | GTCACCGTGCTGCTCAA | 682 to 698 | This study | |
| rpoB-R2 | AGATGTTCGGGATGTCG (CS)d | 2311 to2295 | This study | |
| rpoB-R3 | CACAATGGCGTTCGGCT (CS) | 2898 to2882 | This study | |
| katG-R2 | CCGCCTTTGCTGCTTTC (CS) | 1675 to 1659 | This study | |
| gyrA-F2 | TATCCCGCCGCACAACC | 564 to 580 | This study | |
| gyrA-R2 | GCCCGAGCGATTGGAGT (CS) | 1938 to 1922 | This study | |
| gyrB-F2 | GTCACCGTGCTGCTCAA | 486 to 502 | This study |
a
F, forward; R, reverse.
b
Numbers are based on the nucleotide position relative to the initiation codon of each gene.
c
Sequencing primers for each gene also contain the same forward and reverse primers as PCR amplification for the corresponding gene.
d
CS, complementary strand.